Fox Chase Cancer Center News

PHILADELPHIA (November 26, 2024) — Fox Chase Cancer Center is pleased to announce that Geneviève Almouzni, PhD, is joining the External Advisory Board of the Cancer Epigenetics Institute (CEI).

PHILADELPHIA (November 25, 2024) — Adjuvant therapy regimens inclusive of chemotherapy were independently associated with improved survival in patients with cT2N0 rectal cancer upstaged to T3N0, according to a new study by researchers at Fox Chase Cancer Center and Temple Health.

PHILADELPHIA (November 21, 2024) — Jeffrey M. Farma, MD, FACS, Chair of the Department of Surgery at Fox Chase Cancer Center, recently received a Pennsylvania Impact Award.

PHILADELPHIA (November 20, 2024) — Lu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program and member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, has received a $250,000 grant to further investigate the role of RNA and the formation of liquid droplet structures within cancer cells.

PHILADELPHIA (November 19, 2024) — A team of lung cancer specialists from Fox Chase Cancer Center and Temple Health was recently recognized by the International Association for the Study of Lung Cancer (IASLC) as the winners of the North American Cancer Care Team Award (CCTA) during this year’s annual meeting in San Diego.

PHILADELPHIA (November 19, 2024) — A study led by a researcher at Fox Chase Cancer Center provides new insights into the cellular composition and microenvironment — the noncancerous cells and molecules surrounding tumor cells — of small cell lung cancer. The research team also identified two cellular signaling pathways that play a significant role in the cancer’s aggressiveness.

PHILADELPHIA (November 14, 2024) — Richard J. Bleicher, MD, FACS, Chief of the Division of Breast Surgery and Clinical Director of the Breast Service Line at Fox Chase Cancer Center, has been appointed Vice Chair of the National Accreditation Program for Breast Centers (NAPBC) and Chair of its Executive Committee.

PHILADELPHIA (November 14, 2024) — In patients with Lynch syndrome, the use of aspirin as a form of chemoprevention is lower than anticipated, according to a new study by researchers at Fox Chase Cancer Center to be presented at the 2024 meeting of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC).